Clinical Trial Update: RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating everolimus (RAD001) in combination with paclitaxel and carboplatin as first-line therapy for advanced large cell lung cancer with neu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Lung Carcinoma
• Neuroendocrine Tumors

Drugs mentioned

• Afinitor (everolimus)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Large Cell, Neuroendocrine Tumors | Phase 4 | Status: COMPLETED | Results posted: 2016-03-30